The expanded approval was based on the single-arm, non-randomized, open-label phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of teplizumab.
Dr Erica Schwartz, nominated to lead the US Centers for Disease Control and Prevention, is highly qualified, according to ...
4P004 represents a first-in-class application of GLP-1 receptor agonism in the intra-articular space, specifically targeting patients with knee osteoarthritis and synovitis who have failed multiple ...
Gabapentinoids are associated with an increased risk for drug poisoning, particularly in the short-term after initiation, according to a study published online ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results